MedPath

A study to assess the effect of Resveratrol and Copper in reducing toxic side-effects of chemotherapy in patients with advanced mouth cancer.

Not Applicable
Conditions
Health Condition 1: null- Operable stage IV squamous cell carcinoma of buccal mucosa patients planned for surgery who have not received any prior treatment.
Registration Number
CTRI/2018/03/012459
Lead Sponsor
TMC Research Administrative Council
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Male or female patients 18 years and above.

2. Patients who have given written informed consent

3. Patients with performance status of 0,1 or 2 (ECOG scale)

4. Treatment naïve operable stage IV squamous cell carcinoma of buccal mucosa patients planned for surgery.

Exclusion Criteria

Medical comorbidities like hypertensive, diabetes mellitus, HbsAg and HIV positive, etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the effect of R-Cu on serum and tumour tissue levels of inflammatory cytokines and circulating chromatin at pre-defined time points in patients with operable stage IV squamous cell carcinoma of buccal mucosa prior to surgery.Timepoint: 2 weeks prior to surgery (Day 0) and then after 7 days (Day 7) and then after 14 days (Day 14).
Secondary Outcome Measures
NameTimeMethod
ot applicableTimepoint: Not applicable
© Copyright 2025. All Rights Reserved by MedPath